Cargando…

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling

BACKGROUND: Lung function, measured as forced expiratory volume in one second (FEV(1)), and exacerbations are two endpoints evaluated in chronic obstructive pulmonary disease (COPD) clinical trials. Joint analysis of these endpoints could potentially increase statistical power and enable assessment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhudenkov, Kirill, Palmér, Robert, Jauhiainen, Alexandra, Helmlinger, Gabriel, Stepanov, Oleg, Peskov, Kirill, Eriksson, Ulf G, Wählby Hamrén, Ulrika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815071/ https://www.ncbi.nlm.nih.gov/pubmed/33488073 http://dx.doi.org/10.2147/COPD.S284720

Ejemplares similares

A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics
por: Zhudenkov, Kirill, et al.
Publicado: (2022)

Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization?
por: Voronova, Veronika, et al.
Publicado: (2017)

Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab
por: Gavrilov, Sergey, et al.
Publicado: (2020)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

Joint longitudinal model-based meta-analysis of FEV(1) and exacerbation rate in randomized COPD trials
por: Llanos-Paez, Carolina, et al.
Publicado: (2023)

Longitudinal change of FEV(1) and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD
por: Jo, Yong Suk, et al.
Publicado: (2019)

Improving the evaluation of COPD exacerbation treatment effects by accounting for early treatment discontinuations: a post-hoc analysis of randomized clinical trials
por: Król, Agnieszka, et al.
Publicado: (2020)

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
por: Singh, Dave, et al.
Publicado: (2022)

Effects of Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study
por: Zendedel, Abolfazl, et al.
Publicado: (2015)

Reliability of FEV(1)/FEV(6) to Diagnose Airflow Obstruction Compared with FEV(1)/FVC: The PLATINO Longitudinal Study
por: Perez-Padilla, Rogelio, et al.
Publicado: (2013)

Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study
por: Azarov, Ivan, et al.
Publicado: (2019)

Variability of FEV(1) and Criterion for Acute Pulmonary Exacerbation
por: Jenkins, Bradlee A., et al.
Publicado: (2014)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

COPD assessment test and FEV(1): do they predict oxygen uptake in COPD?
por: Carvalho-Jr, Luiz Carlos S, et al.
Publicado: (2018)

Association Between Vitamin D Levels and FEV1, Number of Exacerbations, and CAT Score in Stable COPD Patients in Indonesia
por: Soeroto, Arto Yuwono, et al.
Publicado: (2021)

Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis
por: Voronova, Veronika, et al.
Publicado: (2020)

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV(1) – a post-hoc analysis of pooled data
por: Chai, Chee-Shee, et al.
Publicado: (2023)

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
por: Singh, Dave, et al.
Publicado: (2020)

Inflammatory and immunological profiles in patients with COPD: relationship with FEV (1) reversibility
por: Queiroz, Cleriston Farias, et al.
Publicado: (2016)

Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients
por: Mokari-Yamchi, Amin, et al.
Publicado: (2019)

Pulmonary function testing in COPD: looking beyond the curtain of FEV1
por: Kakavas, Sotirios, et al.
Publicado: (2021)

FVC, but not FEV(1,) is associated with clinical outcomes of asthma-COPD overlap
por: An, Tai Joon, et al.
Publicado: (2022)

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
por: Peskov, Kirill, et al.
Publicado: (2019)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

Fixed Cut-Off for FEV1/FEV6 and FEV6 in Detection of Obstructive and Restrictive Patterns
por: Aghili, Rokhsareh, et al.
Publicado: (2013)

Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement
por: Jones, Paul, et al.
Publicado: (2012)

Risk factors for FEV(1) decline in mild COPD and high-risk populations
por: Chen, Shujing, et al.
Publicado: (2017)

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers
por: Cullberg, Marie, et al.
Publicado: (2018)

Lower FEV(1) in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV(1), total IgE levels, and TSLP genotypes
por: Masuko, Hironori, et al.
Publicado: (2011)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
por: Bouzek, Drake C., et al.
Publicado: (2022)

Median regression spline modeling of longitudinal FEV(1) measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients
por: Conrad, Douglas J., et al.
Publicado: (2017)

Sputum cell counts to manage prednisone-dependent asthma: effects on FEV(1) and eosinophilic exacerbations
por: Aziz-Ur-Rehman, Afia, et al.
Publicado: (2017)

Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV(1) decline
por: de Aquino, Carolina Silva Barboza, et al.
Publicado: (2022)

Bronchodilator Response of FEV6 and FEV3 as Surrogates of Forced Vital Capacity
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2014)

Genome organization and molecular characterization of the three Formica exsecta viruses—FeV1, FeV2 and FeV4
por: Dhaygude, Kishor, et al.
Publicado: (2019)

Estimation of TGF-β1 genotypes in Egyptian smokers; association with FEV(1) in COPD patients
por: Bohy, Mohammad El, et al.
Publicado: (2010)

A novel CT-emphysema index/FEV(1) approach of phenotyping COPD to predict mortality
por: Loh, Li-Cher, et al.
Publicado: (2018)

Changes in FEV(1) over time in COPD and the importance of spirometry reference ranges: the devil is in the detail
por: Kirkby, Jane, et al.
Publicado: (2019)

Cut-off value of FEV(1)/FEV(6) as a surrogate for FEV(1)/FVC for detecting airway obstruction in a Korean population
por: Chung, Kyung Soo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a7q8a7tj1u31hpbtthtptro8k3